Dermatologists emphasize treatment should be tailored to meet
individual patients' needs
SCHAUMBURG, Ill., June 4 /PRNewswire-USNewswire/ -- Based on an extensive review of scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with traditional systemic therapies. Recommendations, efficacy and safety for the use of the three U.S. Food & Drug Administration (FDA) approved and most commonly used traditional systemic agents - methotrexate, cyclosporine and acitretin - were outlined.
Published online in the Journal of the American Academy of Dermatology, this is the Academy's fourth of six sections of the guidelines of care for psoriasis, with three previously published sections focusing on general recommendations for the treatment of psoriasis and psoriatic arthritis, as well as the use of biologics and topical therapies.
"While in recent years biologics have changed the treatment of psoriasis, traditional systemic therapies - which are easily administered orally and less expensive than biologics - continue to play an important role in treating psoriasis," said dermatologist David M. Pariser, MD, FAAD, president of the Academy. "The Academy's new evidence-based guidelines are intended as a guide for physicians so the best treatment can be determined for each individual patient. The guideline also discussed any potential side effects or risk factors that need to be evaluated prior to treatment."
Psoriasis is a chronic skin condition, which usually begins before age 35 and is characterized by thick, red, scaly patches that itch and bleed. Although it is a genetic disease, it is not completely understood how it is inherited. However, there are at least eight chromosomes to date that researchers have identified as being li
'/>"/>
| SOURCE American Academy of Dermatology Copyright©2009 PR Newswire. All rights reserved |